Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA7 | P43166 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16329478 | 0.97 | ALDH1A1 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31359527 | 0.97 | ALDH1A1 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12376778 | 0.87 | ALDH1A1 (0.54) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL17013373 | 0.86 | ALDH1A1 (0.55) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL2819829 | 0.86 | CA12 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5687859 | 0.84 | NPC1 (0.49) | NPC1RAB9AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL9419050 | 0.83 | HPGD (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9419049 | 0.83 | HPGD (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5958229 | 0.83 | NPC1 (0.48) | NPC1RAB9AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL20100242 | 0.82 | ESR1 (0.57) | NPC1RAB9AALDH1A1ESR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822949-B9 | FUSED PYRIMIDINES AS INHIBITORS OF IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-01-25 | — | — | EP | disclosed |
| EP-2822949-B1 | FUSED PYRIMIDINES AS INHIBITORS OF IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL MYERS SQUIBB CO (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9387203-B2 | Substituted aminoindane- and aminotetralinecarboxylic acids and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-12 | — | — | US | disclosed |
| US-20150174113-A1 | SUBSTITUTED AMINOINDANE- AND AMINOTETRALINECARBOXYLIC ACIDS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | US | disclosed |
| US-9034882-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2822949-A1 | FUSED PYRIMIDINES AS INHIBITORS OF IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8633200-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-21 | — | — | US | disclosed |
| WO-2013134113-A1 | FUSED PYRIMIDINES AS INHIBITORS OF IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-12 | — | — | WO | disclosed |
| US-20130231331-A1 | Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2013-09-05 | — | — | US | disclosed |
| EP-2614064-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20120225888-A1 | Inhibitors of Human Immunodeficiency Virus Replication | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-06 | — | — | US | disclosed |
| WO-2012033735-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012012322-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20080207528-A1 | Administering derivatives of 4-(3-pyrrolidinyloxy)quinoline | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-08-28 | — | — | US | disclosed |
| US-20080207528-A1 | Administering derivatives of 4-(3-pyrrolidinyloxy)quinoline | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-08-28 | — | — | US | disclosed |
| WO-2008095058-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174113-A1 | SUBSTITUTED AMINOINDANE- AND AMINOTETRALINECARBOXYLIC ACIDS AND THE USE THEREOF | AADAT, DDC, AASDHPPT | CA12 2396/4885CA1 1723/4885CA2 654/4885 |
| US-20120225888-A1 | Inhibitors of Human Immunodeficiency Virus Replication | EIF2AK2, RTF2, MAVS | CA12 4807/4885CA1 4849/4885CA2 4761/4885 |
| US-20080207528-A1 | Administering derivatives of 4-(3-pyrrolidinyloxy)quinoline | GLS2, SLC10A1, UGT1A1 | CA12 2982/4885CA1 4273/4885CA2 4586/4885 |
| US-20130231331-A1 | Inhibitors of Human Immunodeficiency Virus Replication | EIF2AK2, RTF2, MAVS | CA12 4807/4885CA1 4849/4885CA2 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.